Initially, numerous reports demonstrated that a high number of DKA cases related to SGLT2-i administration involves patients with T1DM; in these patients, insulin deficiency was considered the major trigger for the development of euDKA. Here, SLC5A2 is linked to type 1 diabetes mellitus.